Clinical Trials
5 trialsNCT06579196 2025-07-24
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1
University of Nebraska
Phase 1/2 Recruiting
NCT05935774 2023-08-25
OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer
University of Washington
Phase 2 Withdrawn
NCT00844064 2019-02-15
Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2
Isarna Therapeutics GmbH
Phase 1 Completed
NCT00761280 2014-11-14
SAPPHIRE
Isarna Therapeutics GmbH
Phase 3 Terminated
NCT00431561 2013-12-03
Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
Isarna Therapeutics GmbH
Phase 2 Completed